Drugs / LMV-12
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06109558 | Dec 2023 → Dec 2026 expected | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMV-12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06109558 ↗ |
| Known as | HE003 | “LMV-12(HE003), 30mg or 60mg, continuously for 21 days” NCT06109558 ↗ |